Glycosylation Profiling of Therapeutic Antibodies in Serum Samples Using a Microfluidic CD Platform and MALDI-MS
Authors:
- 30 April 2013
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 24 (7) , 1053-1063
Abstract
The serum clearance rate of therapeutic antibodies is important as it affects the clinical efficacy, required dose, and dose frequency. The glycosylation of antibodies has in some studies been shown to have an impact on the elimination rates in vivo. Monitoring changes to the glycan profiles in pharmacokinetics studies can reveal whether the clearance rates of the therapeutic antibodies depend on the different glycoforms, thereby providing useful information for improvement of the drugs. In this paper, a novel method for glycosylation analysis of therapeutic antibodies in serum samples is presented. A microfluidic compact-disc (CD) platform in combination with MALDI-MS was used to monitor changes to the glycosylation profiles of samples incubated in vitro. Antibodies were selectively purified from serum using immunoaffinity capture on immobilized target antigens. The glycans were enzymatically released, purified, and finally analyzed by MALDI-TOF-MS. To simulate changes to glycan profiles after administration in vivo, a therapeutic antibody was incubated in serum with the enzyme α1-2,3 mannosidase to artificially reduce the amount of the high mannose glycoforms. Glycan profiles were monitored at specific intervals during the incubation. The relative abundance of the high mannose 5 glycoform was clearly found to decrease and, simultaneously, that of high mannose 4 increased over the incubation period. The method can be performed in a rapid, parallel, and automated fashion for glycosylation profiling consuming low amounts of samples and reagents. This can contribute to less labor work and reduced cost of the studies of therapeutic antibodies glycosylation in vitro and in vivo. Figure ᅟThis publication has 18 references indexed in Scilit:
- High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humansGlycobiology, 2011
- Parallel sample preparation of proteins, from crude samples to crystals ready for MALDI-MS, in an integrated microfluidic systemJournal of Chromatography B, 2010
- Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of actionTrends in Pharmacological Sciences, 2009
- The effect of Fc glycan forms on human IgG2 antibody clearance in humansGlycobiology, 2008
- Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in miceBiologicals, 2008
- Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex typesGlycobiology, 2006
- Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.Journal of Experimental Medicine, 1994
- Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domainsMolecular Immunology, 1992
- Serum IgG subclass concentrations in healthy subjects at different age: Age normal percentile chartsEuropean Journal of Pediatrics, 1989
- Carbohydrate-Specific Receptors of the LiverAnnual Review of Biochemistry, 1982